Open AccessChemotherapy: Impact on Anti- Müllerian Hormone Levels in Breast Carcinoma
Author(s) -
Jyoti Bala,
Shashi Seth,
Rakesh Dhankhar,
Veena Singh Ghalaut
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/15933.7328
Subject(s) - anti müllerian hormone , medicine , ovarian reserve , breast cancer , chemotherapy , breast carcinoma , oncology , hormone , gynecology , cancer , biology , infertility , pregnancy , genetics
Anti-Mullerian Hormone (AMH) is a glycoprotein of the transforming growth factor-β (TGF-β) family that seems to reflect the continuous non-cyclical growth of small follicles and can be considered an indirect index of the size of the resting primordial follicle pool. Accordingly, AMH represents a marker of Ovarian Reserve (OR) and is particularly useful in demonstrating ovarian tissue damage induced by chemotherapy.